DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, J. T.
Right arrow Articles by Phillips, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, J. T.
Right arrow Articles by Phillips, D. L.

Vol. 30, Issue 1, 27-33, January 2002

The Disposition, Metabolism, and Pharmacokinetics of a Selective Metabotropic Glutamate Receptor Agonist in Rats and Dogs

Jason T. Johnson, Edward L. Mattiuz, Sylvia H. Chay, Jennifer L. Herman, William J. Wheeler, Kelem Kassahun, Steven P. Swanson, and Diane L. Phillips

Lilly Research Laboratories, Department of Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana

Compound LY354740 [(+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid], an analog of glutamic acid, is a selective group 2 metabotropic glutamate receptor agonist in clinical development for the treatment of anxiety. Studies have been conducted to characterize the absorption, disposition, metabolism, and excretion of LY354740 in rats and dogs after intravenous bolus or oral administration. Plasma concentrations of LY354740 were measured using a validated gas chromatography/mass spectrometry assay. In rats, LY354740 demonstrated linear pharmacokinetics after oral administration from 30 to 1000 mg/kg. The oral bioavailability of LY354740 was approximately 10% in rats and 45% in dogs. In the dog, food decreased the mean area under the plasma concentration-time curve value by approximately 34%, hence, decreasing the oral bioavailability of the compound. Excretion studies in both rats and dogs indicate that the absorbed drug is primarily eliminated via renal excretion. In addition, tissue distribution in rats showed that the highest levels of radioactivity were in the kidney and gastrointestinal tract, which is consistent with the excretion studies. Metabolism of LY354740 was evaluated in vitro using rat and dog liver microsomes and rat liver slices. In addition, urine and fecal samples from rat and dog excretion studies were profiled using HPLC with radio-detection. These evaluations indicated that neither rats nor dogs metabolized LY354740. In summary, LY354740 is poorly absorbed in rats, moderately absorbed in dogs, and rapidly excreted as unchanged drug in the urine.

Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
M. V. S. Varma, A. H. Eriksson, G. Sawada, Y. A. Pak, E. J. Perkins, and C. L. Zimmerman
Transepithelial Transport of the Group II Metabotropic Glutamate 2/3 Receptor Agonist (1S,2S,5R,6S)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY354740) and Its Prodrug (1S,2S,5R,6S)-2-[(2'S)-(2'-Amino)propionyl]aminobicyclo[3.1.0]hexane-2,6-dicarboxylate (LY544344)
Drug Metab. Dispos., January 1, 2009; 37(1): 211 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
E. J. Perkins and T. Abraham
Pharmacokinetics, Metabolism, and Excretion of the Intestinal Peptide Transporter 1 (SLC15A1)-Targeted Prodrug (1S,2S,5R,6S)-2-[(2'S)-(2-Amino)propionyl]aminobicyclo[3.1.0.]hexen-2,6-dicarboxylic acid (LY544344) in Rats and Dogs: Assessment of First-Pass Bioactivation and Dose Linearity
Drug Metab. Dispos., October 1, 2007; 35(10): 1903 - 1909.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. M. Rorick-Kehn, B. G. Johnson, J. L. Burkey, R. A. Wright, D. O. Calligaro, G. J. Marek, E. S. Nisenbaum, J. T. Catlow, A. E. Kingston, D. D. Giera, et al.
Pharmacological and Pharmacokinetic Properties of a Structurally Novel, Potent, and Selective Metabotropic Glutamate 2/3 Receptor Agonist: In Vitro Characterization of Agonist (-)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic Acid (LY404039)
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 308 - 317.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. M. Rorick-Kehn, E. J. Perkins, K. M. Knitowski, J. C. Hart, B. G. Johnson, D. D. Schoepp, and D. L. McKinzie
Improved Bioavailability of the mGlu2/3 Receptor Agonist LY354740 Using a Prodrug Strategy: In Vivo Pharmacology of LY544344
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 905 - 913.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
R. Galici, N. G. Echemendia, A. L. Rodriguez, and P. J. Conn
A Selective Allosteric Potentiator of Metabotropic Glutamate (mGlu) 2 Receptors Has Effects Similar to an Orthosteric mGlu2/3 Receptor Agonist in Mouse Models Predictive of Antipsychotic Activity
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1181 - 1187.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
J. K. James, M. Nakamura, A. Nakazato, K. E. Zhang, M. Cramer, J. Brunner, J. Cook, and W. G. Chen
METABOLISM AND DISPOSITION OF A POTENT GROUP II METABOTROPIC GLUTAMATE RECEPTOR AGONIST, IN RATS, DOGS, AND MONKEYS
Drug Metab. Dispos., September 1, 2005; 33(9): 1373 - 1381.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.